Joan Lucca

1.6k total citations
25 papers, 1.0k citations indexed

About

Joan Lucca is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joan Lucca has authored 25 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Joan Lucca's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (12 papers). Joan Lucca is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (12 papers). Joan Lucca collaborates with scholars based in United States, Japan and Spain. Joan Lucca's co-authors include Thomas J. Lynch, Bruce E. Johnson, Patricia Ostler, Pasi A. Jänne, Arthur T. Skarin, Beow Y. Yeap, David M. Jackman, Michael S. Rabin, Panos Fidias and Panos Fidias and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Oncotarget.

In The Last Decade

Joan Lucca

25 papers receiving 990 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joan Lucca United States	12	753	683	196	73	62	25	1.0k
Gianfranco Buccheri Italy	19	573 0.8×	548 0.8×	242 1.2×	107 1.5×	88 1.4×	50	991
Francesca Mazzoni Italy	18	470 0.6×	568 0.8×	178 0.9×	63 0.9×	160 2.6×	63	821
Akitaka Makiyama Japan	17	412 0.5×	715 1.0×	193 1.0×	59 0.8×	74 1.2×	116	994
Kiichiro Ninomiya Japan	16	474 0.6×	512 0.7×	138 0.7×	70 1.0×	67 1.1×	81	715
Yenting Ngai United Kingdom	9	381 0.5×	273 0.4×	78 0.4×	89 1.2×	90 1.5×	17	557
Fabio De Vincenzo Italy	18	815 1.1×	254 0.4×	138 0.7×	104 1.4×	60 1.0×	54	1.1k
R. Basser Australia	15	179 0.2×	397 0.6×	199 1.0×	30 0.4×	115 1.9×	31	731
Anna Wrona Poland	12	519 0.7×	449 0.7×	180 0.9×	30 0.4×	96 1.5×	34	692
Sasja F. Mulder Netherlands	12	340 0.5×	253 0.4×	265 1.4×	51 0.7×	130 2.1×	38	669
Andrea Michelotti Italy	17	240 0.3×	746 1.1×	187 1.0×	113 1.5×	263 4.2×	60	1.3k

Countries citing papers authored by Joan Lucca

Since Specialization

Citations

This map shows the geographic impact of Joan Lucca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Lucca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Lucca more than expected).

Fields of papers citing papers by Joan Lucca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Lucca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Lucca. The network helps show where Joan Lucca may publish in the future.

Co-authorship network of co-authors of Joan Lucca

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Lucca. A scholar is included among the top collaborators of Joan Lucca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Lucca. Joan Lucca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lucca, Joan, et al.. (2015). A Structured Nursing Intervention to Address  Oral Chemotherapy Adherence in Patients  With Non-Small Cell Lung Cancer. Oncology nursing forum. 42(4). 383–389. 29 indexed citations

Jackman, David M., L.J.A.M. Jacobs, Joan Lucca, et al.. (2015). A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 6(6). 4527–4536. 79 indexed citations

Redig, Amanda J., Myriam Taibi, Geoffrey R. Oxnard, et al.. (2015). A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression.. Journal of Clinical Oncology. 33(15_suppl). 8076–8076. 2 indexed citations

Gandhi, Leena, Rebecca S. Heist, Joan Lucca, et al.. (2012). A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).. Journal of Clinical Oncology. 30(15_suppl). 7099–7099. 3 indexed citations

Mollerus, Michael, et al.. (2010). Magnetic resonance imaging of pacemakers and implantable cardioverter-defibrillators without specific absorption rate restrictions. EP Europace. 12(7). 947–951. 58 indexed citations

Jänne, Pasi A., Enriqueta Felip, S. Cedrés, et al.. (2009). Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). A254–A254. 1 indexed citations

Jackman, David M., Hedy L. Kindler, Beow Y. Yeap, et al.. (2008). Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 113(4). 808–814. 85 indexed citations

Jackman, David M., Neal I. Lindeman, Joan Lucca, et al.. (2007). P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.. Journal of Thoracic Oncology. 2(8). S720–S720. 1 indexed citations

Jackman, David M., Beow Y. Yeap, Neal I. Lindeman, et al.. (2007). Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(7). 760–766. 254 indexed citations

10.

Jackman, D. M., Neal I. Lindeman, Joan Lucca, et al.. (2007). Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma. Journal of Clinical Oncology. 25(18_suppl). 7591–7591. 8 indexed citations

11.

Jackman, D. M., B.Y. Yeap, Joan Lucca, et al.. (2006). Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. Journal of Clinical Oncology. 24(18_suppl). 7168–7168. 4 indexed citations

12.

Jackman, D. M., Joan Lucca, P. Fidias, et al.. (2005). Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 23(16_suppl). 7148–7148. 15 indexed citations

13.

Jackman, D. M., Joan Lucca, P. Fidias, et al.. (2005). O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Lung Cancer. 49. S62–S63. 2 indexed citations

14.

Jänne, Pasi A., Sarada Gurubhagavatula, Beow Y. Yeap, et al.. (2004). Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study. Lung Cancer. 44(2). 221–230. 169 indexed citations

15.

Lucca, Joan, Michael S. Rabin, Thomas J. Lynch, et al.. (2004). Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 22(14_suppl). 7080–7080. 7 indexed citations

16.

Goffin, John R., Leonard J. Appleman, David P. Ryan, et al.. (2003). P-348 A phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors. Lung Cancer. 41. S179–S180. 7 indexed citations

17.

Jänne, Pasi A., Sarada Gurubhagavatula, Joan Lucca, et al.. (2003). O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program. Lung Cancer. 41. S71–S71. 12 indexed citations

18.

Shapiro, Geoffrey I., Jeffrey G. Supko, Joan Lucca, et al.. (2001). A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.. PubMed. 7(6). 1590–9. 138 indexed citations

19.

Fidias, Panos, Jeffrey G. Supko, Anthony Boral, et al.. (2001). A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.. PubMed. 7(12). 3942–9. 95 indexed citations

20.

Skarin, Arthur T., Joan Lucca, Anthony Boral, et al.. (2000). A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent radiotherapy (CT/RT) in patients (pts) with stage III non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 112–112. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact